News headlines about Oncobiologics (NASDAQ:ONS) have trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Oncobiologics earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.404074347159 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Oncobiologics (ONS) traded down $0.02 during trading hours on Wednesday, reaching $1.17. 275,200 shares of the company traded hands, compared to its average volume of 111,349. Oncobiologics has a twelve month low of $0.78 and a twelve month high of $3.95. The company has a current ratio of 0.03, a quick ratio of 0.03 and a debt-to-equity ratio of -0.01.

TRADEMARK VIOLATION WARNING: “Oncobiologics (ONS) Earns Daily News Impact Score of 0.19” was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/oncobiologics-ons-earns-daily-news-impact-score-of-0-19/1774916.html.

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.

Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.